Literature DB >> 15665648

Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India.

Susan H Eshleman1, Sarah E Hudelson, Amita Gupta, Robert Bollinger, Anand D Divekar, Raman R Gangakhedkar, Smita S Kulkarni, Madhuri R Thakar, Ramesh S Paranjape, Srikanth Tripathy.   

Abstract

India has the second largest burden of HIV-1-infected persons worldwide. Access to antiretroviral drugs in India is increasing. We analyzed HIV-1 protease and reverse transcriptase sequences in 12 acute seroconverters from Pune, India, and evaluated HIV-1 evolution in these individuals over time. HIV-1 genotyping was performed with the ViroSeq HIV-1 Genotyping System. Baseline samples, collected between 1999 and 2001, had viral loads from 3,523 to 8,556,280 copies/ml. All subjects had subtype C HIV-1. None of the samples had primary drug resistance mutations. The sequence identity between baseline and 1-year samples ranged from 99.7% to 99.9%, and between baseline and 2-year samples ranged from 99.4% to 100%. Most of the nucleotide changes were silent (synonymous). Amino acid substitutions were rare, and varied from subject to subject. In this cohort, drug resistance was not observed and evolution in the pol region was very limited during the first 2 years of infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665648     DOI: 10.1089/aid.2005.21.93

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

2.  Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.

Authors:  Narayanaiah Cheedarla; Jagadish Chandrabose Sundaramurthi; Babu Hemalatha; Brahmaiah Anangi; Manohar Nesakumar; Manickam Ashokkumar; K K Vidya Vijayan; Srikanth Prasad Tripathy; Soumya Swaminathan; S Kalyanaraman Vaniambadi; D Vadakkupattu Ramanathan; Luke Elizabeth Hanna
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-20       Impact factor: 2.205

3.  Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.

Authors:  Mary Kearney; Jon Spindler; Wei Shao; Frank Maldarelli; Sarah Palmer; Shiu-Lok Hu; Jeffrey D Lifson; Vineet N KewalRamani; John W Mellors; John M Coffin; Zandrea Ambrose
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

4.  Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

Authors:  Shanmugam Saravanan; Madhavan Vidya; Pachamuthu Balakrishnan; Rami Kantor; Sunil S Solomon; David Katzenstein; Nagalingeswaran Kumarasamy; Tokugha Yeptomi; Sathasivam Sivamalar; Samara Rifkin; Kenneth H Mayer; Suniti Solomon
Journal:  Clin Infect Dis       Date:  2012-02-09       Impact factor: 9.079

5.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

Review 6.  HIV infection in India: epidemiology, molecular epidemiology and pathogenesis.

Authors:  Samir Lakhashe; Madhuri Thakar; Sheela Godbole; Srikanth Tripathy; Ramesh Paranjape
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.